Abstract:5539 Previous studies have suggested that the sphingosine kinase 1 (SPHK1) gene can act as an oncogene, mediating various cellular functions such as cell proliferation, apoptosis inhibition and cell transformation and migration. The current study was conducted to investigate the expression of SPHK1 in human astrocytomas and to characterize its association with the clinical progression of astrocytomas. Our results of Western blotting and RT-PCR showed that SPHK1 mRNA and protein were upregulated in astrocytoma cell lines, as well as in astrocytoma tissues when compared with paired adjacent non-cancerous tissues from the same patients. In addition, 243 paraffin-embedded archival astrocytoma tissues were examined with immunohistochemical staining, among which 227 paraffin-embedded archival astrocytomas biopsies displayed moderate to strong cytoplasmic staining of SPHK1 in astrocytomas cells, whereas no significant staining of SPHK1 was detected in the adjacent non-cancerous epithelial cells. These data supported the notion that SPHK1 might play a role in the development and progression of astrocytomas. Quantitative SPHK1 immunohistochemical staining demonstrated that the SPHK1 expression level increased in parallel with the development and progression of astrocytomas. Further analysis of the relationship between SPHK1 staining and the clinical characteristics of patients showed a significant correlation of SPHK1 expression with the clinocopathological staging, while it was not correlated to the age and gender in astrocytomas patients, strongly suggesting that SPHK1 might be useful as an independent marker to identify subsets of astrocytomas patients with more aggressive disease. Furthermore, patients with high SPHK1 expression revealed a cumulative 3-year survival rate of 10.3% (n=100, 95% confidence interval, 0.041-0.165), as compared with the 57.7% (95% confidence interval, 0.517-0.637) cumulative 3-year survival rate in the low SPHK1 group (n =143), suggesting the possibility to use SPHK1 as a predictor for patient prognosis and survival. It is also noteworthy that the predictive significance of SPHK1 expression for poorer prognosis was identified in both relatively early- (grade I and II) and late-stage (grade III and IV) patient subgroups. Taken together, our data strongly suggest the usefulness of SPHK1 expression as a prognostic marker for astrocytoma patients.

Expression of FAK and Pyk2 in Human Astrocytic Tumors and its Relationship with Angiogenesis

Expression of Enos and VEGF in Association with Angiogenesis of Human Astrocytoma

Expression of Endothelial Nitric Oxide Synthase and Vascular Endothelial Growth Factor in Association with Neovascularization in Human Primary Astrocytoma.

Expression and significance of vascuIar endothelial growth factor and VIII-R Ag in human brain glioma

Expression and significance of vascuIar endothelial growth factor and Ⅷ-R Ag in human brain glioma

Clinical Implications of VEGF and Ki-67 Expression in Astrocytic Tumor Patients

Expressions and significance of survivin and FAK in human astrocytoma

Role of Urokinase-type Plasminogen Activator and Vascular Endothelial Growth Factor and the Correlation in Human Astrocytomas Invasion

Expressions of vascular endothelial growth factor gene protein in astrocytoma and its clinical significance

[Expression of Vascular Endothelial Growth Factor in Brain Astrocytoma and Its Clinical Evaluation].

P53 and Vascular Endothelial Growth Factor Expression in Astrocytoma and Their Relation to Angiogenesis

The expressions of VEGF and COX- 2 protein in astrocytoma

Proline-Rich Protein Tyrosine Kinase 2 in Inflammation and Cancer

Expression of EphA2 in Human Astrocytic Tumors: Correlation with Pathologic Grade, Proliferation and Apoptosis

The expression and significance of FAK in humanastroglioma

Expression of PTEN in Human Glioma and its Relationship with FAKpY397 and MVD

High Expression of Proline-Rich Tyrosine Kinase2 is Associated with Poor Survival of Hepatocellular Carcinoma Via Regulating Phosphatidylinositol 3-Kinase/akt Pathway

The Clinical Significance of Sphk1 Expression in Human Astrocytomas Progression and Overall Patient Survival

Induction of Proline-Rich Tyrosine Kinase 2 Activation-Mediated C6 Glioma Cell Invasion after Anti-Vascular Endothelial Growth Factor Therapy.

Comprehensive pan-cancer analysis of 33 human cancers reveals immunotherapeutic value of focal adhesion tyrosine kinase

Clinical Significance of Sphingosine Kinase-1 Expression in Human Astrocytomas Progression and Overall Patient Survival